HAVCR2 and triple-negative breast carcinoma: A recent study by Rozalén and collaborators (2025) extends these latter observations by demonstrating that triple-negative breast cancer (TNBC) cells that express the co-inhibitory receptor hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) are superior at establishing metastatic lesions compared to their TIM-3- counterparts, at least in part through the interleukin 1 beta (IL1B, best known as IL-1β)-dependent recruitment of IL-17+ γδ T cells, which contribute to the establishment of local immunosuppression and overt immunoevasion (Galassi et al, 2024; Rozalen et al, 2025).